Applied Therapeutics (APLT) Price & Analysis

Compare

787 Followers

APLT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.30 - $10.62

Previous CloseN/A

Volume3.84M

Average Volume (3M)1.47M

Market Cap

$63.58M

Enterprise Value$38.22M

Total Cash (Recent Filing)$50.76M

Total Debt (Recent Filing)$2.70M

Price to Earnings (P/E)―

Beta1.30

Next Earnings

Nov 06, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding141,575,530

10 Day Avg. Volume764,845

30 Day Avg. Volume1,465,601

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.60

Enterprise Value/Revenue144.22

Enterprise Value/Gross Profit-538.30

Enterprise Value/Ebitda-0.35

Forecast

1Y Price Target

$2.25

Price Target Upside400.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Efficacy Of TreatmentAnalyst is encouraged by the strong effect on sorbitol and on a patient-reported outcome, the CMT-Health Index (CMT-HI), especially since these effects were maintained through 24 months.

Leadership ChangesAPLT announced the former CEO would step down and be replaced by John H. Johnson, an industry veteran with more than 40 years of experience, who now serves as Executive Chairman.

Management StrengthNew management has been focused on executing on their operational, regulatory, and clinical goals, positioning APLT in a stronger position across these strategies.

Bears Say

Financial RiskThe company is seen as bearing increased financial risk given its limited cash runway.

Regulatory ChallengesThe company requested a meeting with the Office of Scientific Investigations to discuss the matter but was not granted a meeting.

Regulatory Timeline UncertaintyThe recent FDA turnover and uncertainty on the timeline for FDA alignment have led to a push back of the launch of govorestat in galactosemia and SORD deficiency to the third quarter of 2026 in the model.

Applied Therapeutics News

Applied Therapeutics Faces Nasdaq Listing Challenge

Applied Therapeutics ( ($APLT) ) has issued an announcement. On February 7, 2025, Applied Therapeutics received a notification...

16h ago

APLT

Applied Therapeutics Announces New Chief Medical Officer

Applied Therapeutics ( ($APLT) ) just unveiled an announcement. On June 17, 2025, Applied Therapeutics announced the departure...

2M ago

APLT

Applied Therapeutics CMO Riccardo Perfetti to depart, Evan Bailey to succeed

Applied Therapeutics (APLT) announced the promotions of Evan Bailey to chief medical officer, effective June 15 and Dottie...

2M ago

APLT

Applied Therapeutics Elects New Director at Annual Meeting

The latest update is out from Applied Therapeutics ( ($APLT) ). At the 2025 Annual Meeting of Stockholders...

2M ago

APLT

Hold Rating for Applied Therapeutics Amid Mixed Results from Govorestat Trial

William Blair analyst Sami Corwin has reiterated their neutral stance on APLT stock, giving a Hold rating on...

3M ago

APLT

Applied announces INSPIRE Phase 2/3 trial primary endpoint not significant

Applied Therapeutics (APLT) presented full 12-month clinical results and new topline data from 18 and 24 months from...

3M ago

APLT

Strategic Advancements and Regulatory Progress Drive Buy Rating for Applied Therapeutics

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Applied Therapeutics (APLT – Research Report) on May...

3M ago

APLT

Applied Therapeutics Reports Q1 2025 Financial Results

Applied Therapeutics ( ($APLT) ) has released its Q1 earnings. Here is a breakdown of the information Applied...

3M ago

APLT

Applied Therapeutics reports Q1 EPS (15c), consensus (18c)

Cash and cash equivalents and short-term investments totaled $50.8M as of March 31, compared with $79.4M at December...

3M ago

APLT

Applied Therapeutics to present full 12-month INSPIRE Phase 3 results

Applied Therapeutics (APLT) announced its late-breaking abstract for govorestat, or AT-007, has been selected for oral presentation at...

3M ago

APLT

Applied Therapeutics Reports 2024 Financial Results and Leadership Changes

Applied Therapeutics ( ($APLT) ) has released its Q4 earnings. Here is a breakdown of the information Applied...

4M ago

APLT

Applied Therapeutics reports FY24 EPS (76c), consensus ($1.33)

Reports FY24 revenue $455K, consensus $553k. Reports cash, cash equivalents of $79.4M as of December 31, 2024. “We...

4M ago

APLT

Applied Therapeutics Delays Yearly Report Filing

Applied Therapeutics ( ($APLT) ) has released a notification of late filing. Applied Therapeutics, Inc. has announced a...

4M ago

APLT

Applied Therapeutics files Form 12b-25 with SEC

Applied Therapeutics (APLT) has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange...

4M ago

APLT

APLT FAQ

What was Applied Therapeutics Inc’s price range in the past 12 months?

Applied Therapeutics Inc lowest stock price was $0.29 and its highest was $10.62 in the past 12 months.

What is Applied Therapeutics Inc’s market cap?

Applied Therapeutics Inc’s market cap is $63.58M.

When is Applied Therapeutics Inc’s upcoming earnings report date?

Applied Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 85 days.

How were Applied Therapeutics Inc’s earnings last quarter?

Currently, no data Available

Is Applied Therapeutics Inc overvalued?

According to Wall Street analysts Applied Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Applied Therapeutics Inc pay dividends?

Applied Therapeutics Inc does not currently pay dividends.

What is Applied Therapeutics Inc’s EPS estimate?

Applied Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Applied Therapeutics Inc have?

Applied Therapeutics Inc has 141,575,530 shares outstanding.

What happened to Applied Therapeutics Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Applied Therapeutics Inc?

Currently, no hedge funds are holding shares in APLT

Applied Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-83.71%

Trailing 12-Months

Asset Growth

-62.37%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Applied Therapeutics Inc

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Applied Therapeutics (APLT) Earnings & Revenues

Historic Earnings Reports

APLT Stock 12 Month Forecast

Average Price Target

$2.25

▲(400.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Sep<br/>2024","9":"Dec<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.41,0.6092307692307692,0.8084615384615383,1.0076923076923077,1.2069230769230768,1.406153846153846,1.6053846153846152,1.8046153846153843,2.003846153846154,2.203076923076923,2.402307692307692,2.6015384615384614,2.8007692307692307,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.41,0.5515384615384615,0.6930769230769231,0.8346153846153846,0.9761538461538461,1.1176923076923078,1.2592307692307694,1.4007692307692308,1.5423076923076924,1.683846153846154,1.8253846153846156,1.966923076923077,2.1084615384615386,{"y":2.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.41,0.4938461538461538,0.5776923076923077,0.6615384615384615,0.7453846153846153,0.8292307692307692,0.9130769230769231,0.9969230769230768,1.0807692307692307,1.1646153846153846,1.2484615384615385,1.3323076923076922,1.416153846153846,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.12,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.33,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.44,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.66,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.34,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.39,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.41,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >